natgillin/translations-raw huggingface dataset:
Therefore, breast-feeding is not recommended during treatment with IVEMEND. 
Zato med zdravljenjem z zdravilom IVEMEND dojenje ni priporočljivo.
The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. 
Pri 3-dnevnem režimu zdravljenja s peroralnim aprepitantom se je AUC substratov za CYP2C9 zmanjšala za približno 30-35 %, koncentracija etinilestradiola tik pred naslednjim odmerkom pa za do 64 %.
Instructions of how to reconstitute and dilute IVEMEND 150 mg 
Navodila za rekonstitucijo in redčenje zdravila IVEMEND 150 mg
• Volume to administer (ml) = recommended dose (mg/kg) x weight (kg) o Note: Do not exceed maximum doses (see section 4.2). 
• Količina za apliciranje (ml) = priporočeni odmerek (mg/kg) x telesna masa (kg) o Opomba: Ne prekoračite največjih odmerkov (glejte poglavje 4.2).
The most common adverse reactions reported at a greater incidence in adults treated with the aprepitant regimen than with standard therapy in patients receiving HEC were: hiccups (4.6 % versus 2.9 %), alanine aminotransferase (ALT) increased (2.8 % versus 1.1 %), dyspepsia (2.6 % versus 2.0 %), constipation (2.4 % versus 2.0 %), headache (2.0 % versus 1.8 %), and decreased appetite (2.0 % versus 0.5 %). 
Najpogostejši neželeni učinki pri zelo emetogeni kemoterapiji (HEC), o katerih so pri odraslih, ki so se zdravili z aprepitantom, poročali pogosteje kot pri bolnikih med standardno obliko zdravljenja so: kolcanje (4,6 % proti 2,9 %), zvišana vrednost alanin aminotransferaze (ALT ) (2,8 % proti 1,1 %), dispepsija (2,6 % proti 2,0 %), zaprtje (2,4 % proti 2,0 %), glavobol (2,0 % proti 1,8 %) in zmanjšan apetit (2,0 % proti 0,5 %).
Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant (see section 5.2). 
Fosaprepitant je predzdravilo aprepitanta, ki se po intravenski aplikaciji hitro pretvori v aprepitant (glejte poglavje 5.2).
The powder is reconstituted and diluted before use. 
Pred uporabo je treba prašek raztopiti in razredčiti.
Additionally, in a placebo-controlled clinical trial in adult patients receiving MEC, safety was evaluated for 504 patients receiving a single dose of IVEMEND 150 mg compared to 497 patients receiving the control regimen. 
Poleg tega so v s placebom nadzorovanem kliničnem preskušanju pri odraslih bolnikih, ki so prejemali MEC, ovrednotili varnost pri 504 bolnikih, ki so prejeli enkraten odmerek zdravila IVEMEND 150 mg, in pri 497 bolnikih, ki so prejeli kontrolno shemo zdravljenja.
The medicinal product must not be reconstituted or mixed with solutions for which physical and chemical compatibility has not been established (see Summary of Product Characteristic (SmPC), section 6.2). 
Zdravila ne smete pripravljati ali mešati z raztopinami, za katere ni bila dokazana fizikalna in kemična kompatibilnost (glejte poglavje 6.2 Povzetka glavnih značilnosti zdravila (SmPC)).
In patients with ESRD undergoing haemodialysis, the AUC0- of total aprepitant decreased by 42 % and Cmax decreased by 32 %. 
Pri bolnikih s končno ledvično odpovedjo na hemodializi je bila AUC0- celokupnega aprepitanta za 42 % manjša, Cmax pa za 32 % nižja.
Because of the antiemetic activity of aprepitant, emesis induced by a medicinal product may not be effective. 
Zaradi antiemetičnega delovanja aprepitanta zdravljenje z zdravili za spodbujanje bruhanja lahko ne bo učinkovito.
Your doctor may ask you to take other medicines including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist' (such as ondansetron) for preventing nausea and vomiting. 
Zdravnik vam bo morda naročil, da uporabljate druga zdravila za preprečevanje navzee (siljenja na bruhanje) in bruhanja, vključno s kortikosteroidom (kot je deksametazon) in zaviralcem 5HT3 (kot je ondansetron).
An interaction with orally administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g. etoposide, vinorelbine) cannot be excluded. 
Interakcij s peroralno danimi kemoterapevtiki, ki se primarno ali delno presnavljajo s CYP3A4 (npr. etopozid, vinorelbin), ne moremo izključiti.
Positron emission tomography (PET) imaging studies, using a highly specific NK1-receptor tracer, in healthy young men administered a single intravenous dose of 150 mg fosaprepitant (N=8) demonstrated brain NK1 receptor occupancy of ≥100 % at Tmax, and 24 hours, ≥97 % at 48 hours, and between 41 % and 75 % at 120 hours, following dosing. 
Pri študijah s pozitronsko emisijsko tomografijo (PET) so pri zdravih mladih moških, ki so prejeli enkratni intravenski odmerek 150 mg fosaprepitanta (N = 8), z uporabo visoko specifičnega označevalca receptorjev NK1 ugotovili, da je zasedenost možganskih receptorjev NK1 ≥ 100 % pri Tmax in po 24 urah, ≥ 97 % po 48 urah in med 41 % in 75 % po 120 urah po prejemu odmerka.
Control regimen (N =498) ** 
Kontrolna shema (N = 498) **
IVEMEND should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below. 
Zdravilo IVEMEND se mora dati v kombinaciji s kortikosteroidom in z antagonistom 5-HT3, kot je razloženo v naslednjih preglednicah.
The appearance of the reconstituted solution is the same as the appearance of the diluent. 
Videz rekonstituirane raztopine je enak videzu topila.
Depending on the chemotherapy treatment, there are two ways IVEMEND may be given: IVEMEND is given only on Day 1 (single day of chemotherapy) IVEMEND is given on Day 1, 2, and 3 (single or multiple days of chemotherapy) o Oral formulations of aprepitant may be prescribed on Days 2 and 3 instead of IVEMEND. 
Zdravilo IVEMEND je mogoče uporabiti na dva načina, odvisno od kemoterapije: Zdravilo IVEMEND se uporabi le 1. dan (kemoterapija le en dan) Zdravilo IVEMEND se uporabi 1., 2. in 3. dan (kemoterapija en dan ali več dni) o Namesto zdravila IVEMEND je mogoče 2. in 3. dan predpisati peroralne oblike aprepitanta.
Intravenous administration in paediatric patients aged 6 months and older is recommended through a central venous catheter and should be administered over 30 minutes in patients aged 12 years and older or over 60 minutes in patients less than 12 years of age (See section 6.6). 
Pri pediatričnih bolnikih, starih 6 mesecev ali več, je intravensko dajanje zdravila priporočljivo izvesti po centralnem venskem katetru; pri bolnikih, starih 12 let ali več, mora infundiranje trajati 30 minut, pri bolnikih, mlajših od 12 let, pa 60 minut (glejte poglavje 6.6).
In the same analysis, safety was evaluated for 199 patients receiving either HEC or MEC and a single dose of IVEMEND at or above the recommended 3-day regimen of IVEMEND. 
V isti analizi so varnost ocenili pri 199 bolnikih, ki so prejemali ali HEC ali MEC in enkratni odmerek zdravila IVEMEND v priporočeni 3-dnevni odmerni shemi zdravila IVEMEND ali več.
Aprepitant is excreted in the milk of lactating rats after intravenous administration of fosaprepitant as well as after oral administration of aprepitant. 
Aprepitant so zasledili v mleku doječih podgan tako po intravenskem dajanju fosaprepitanta kot po peroralnem dajanju aprepitanta.
Fosaprepitant placebo and dexamethasone placebo (on Day 1) were used to maintain blinding. 
Fosaprepitant placebo in deksametazon placebo (1. dan) so uporabili z namenom, da je bila študija slepa.
Withdraw the entire volume from the vial and transfer it into an infusion bag containing 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection to yield a total volume of 150 ml and final concentration of 1 mg/ml. 
Iz viale izvlecite celoten volumen raztopine in jo dodajte v infuzijsko vrečko s 145 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje, da dobite skupni volumen 150 ml in končno koncentracijo 1 mg/ml.
The adverse reactions profiles in the Multiple-Cycle extension of HEC and MEC studies in adults for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1. 
Profili neželenih učinkov so bili v podaljšku HEC in MEC študij pri odraslih z več ciklusi zdravljenja (do 6 dodatnih ciklusov kemoterapije) na splošno podobni tistim po prvem ciklusu.
Aprepitant cannot be removed by haemodialysis. 
Aprepitanta iz telesa ni mogoče odstraniti s hemodializo.
Intravenous administration in adults occurs preferably through a running intravenous infusion over 20-30 minutes. 
Pri odraslih je zdravilo najbolje aplicirati v obliki 20-30-minutne intravenske infuzije.
When using combined IVEMEND and EMEND regimens, please refer to the Summary of Product Characteristics (SmPC) section 4.5 for EMEND capsules or EMEND for oral suspension. 
V primeru uporabe kombiniranih shem z zdraviloma IVEMEND in EMEND glejte poglavje 4.5 Povzetka glavnih značilnosti zdravila (SmPC) kapsul EMEND oziroma peroralne suspenzije EMEND.
Parenteral medicines should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit. 
Zdravila za parenteralno uporabo morate pred aplikacijo pregledati glede tujih delcev ali spremembe barve vedno, kadar raztopina in vsebnik to omogočata.
6 - < 12 years old 
6 - < 12 let
In a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day. 
V študiji toksičnosti pri mladih psih, ki so od 14. do 42. dne postnatalno prejemali fosaprepitant, so pri samcih opažali manjšo maso testisov in manjšo velikost Leydigovih celic pri odmerku 6 mg/kg/dan, pri samicah pa večjo maso maternice, hipertrofijo maternice in materničnega vratu ter edem nožničnih tkiv pri odmerkih od 4 mg/kg/dan.
- The other ingredients are: disodium edetate (E386), polysorbate 80 (E433), lactose anhydrous, sodium hydroxide (E524) (for pH adjustment) and/or hydrochloric acid diluted (E507) (for pH adjustment). 
- Druge sestavine zdravila (pomožne snovi) so: dinatrijev edetat (E386), polisorbat 80 (E433), brezvodna laktoza, natrijev hidroksid (E524) (za uravnavo pH) in/ali razredčena klorovodikova kislina (E507) (za uravnavo pH).
Table 7: Percent of adult patients receiving Highly Emetogenic Chemotherapy responding by treatment group and phase - Cycle 1 
Preglednica 7: Odstotek odraslih bolnikov, ki so prejemali zelo emetogeno kemoterapijo z odzivom po zdravljenih skupinah in fazi - 1. ciklus
In humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion. 
Pri človeku se fosaprepitant hitro pretvori v aprepitant, v 30 minutah po koncu infundiranja.
Metabolites are excreted in urine and via biliary excretion in faeces. 
Presnovki se izločajo z urinom ter prek izločanja z žolčem v blatu.
Dexamethasone: The oral dexamethasone dose should be reduced by approximately 50 % when coadministered with fosaprepitant (see section 4.2). 
Deksametazon: Pri uporabi fosaprepitanta je treba peroralni odmerek deksametazona zmanjšati za približno 50 % (glejte poglavje 4.2).
The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table. 
Kategorije pogostnosti v preglednici temeljijo na študijah pri odraslih; v študijah pri pediatričnih bolnikih so bile opažene pogostnosti podobne ali manjše, razen če je drugače navedeno v preglednici.
• Volume to administer (ml) = recommended dose (mg/kg) x weight (kg) o Note: Do not exceed maximum doses (see Summary of Product Characteristic (SmPC), section 4.2). 
• Količina za apliciranje (ml) = priporočeni odmerek (mg/kg) x telesna masa (kg) o Opomba: Ne prekoračite največjih odmerkov (glejte poglavje 4.2 Povzetka glavnih značilnosti zdravila (SmPC)).
In patients with severe renal impairment, the AUC0- of total aprepitant (unbound and protein bound) decreased by 21 % and Cmax decreased by 32 %, relative to healthy subjects. 
Pri bolnikih s hudo okvaro ledvic je bila AUC0- celokupnega aprepitanta (nevezanega in vezanega na beljakovine) za 21 % manjša, Cmax pa za 32 % nižja kot pri zdravih preiskovancih.
After reconstitution and dilution: 24 hours at 25°C. 
Po rekonstituciji in redčenju: 24 ur pri temperaturi 25 °C.
It is anticipated that fosaprepitant would cause less or no greater induction of CYP2C9, CYP3A4 and glucuronidation than that caused by the administration of oral aprepitant. 
Pričakujemo, da fosaprepitant povzroči manjšo ali pa vsaj ne večje indukcije CYP2C9, CYP3A4 in glukuronidacije v primerjavi s peroralnim aprepitantom.
Interaction studies with fosaprepitant 150 mg and 5-HT3 antagonists have not been conducted; however, in clinical interaction studies, the oral aprepitant regimen did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron). 
Študij medsebojnega delovanja fosaprepitanta 150 mg in antagonistov 5-HT3 niso izvedli; vendar pa v kliničnih študijah medsebojnega delovanja zdravljenje s peroralnim aprepitantom ni imelo klinično pomembnih učinkov na farmakokinetiko ondansetrona, granisetrona ali hidrodolasetrona (aktivnega presnovka dolasetrona).
All metabolites observed in urine, faeces and plasma following an intravenous 100 mg [ 
Vsi presnovki, opaženi v urinu, blatu in plazmi po 100 mg intravenskem odmerku [
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml). 
Po rekonstituciji in redčenju 1 ml raztopine vsebuje 1 mg fosaprepitanta (1 mg/ml).
Gently invert the bag 2-3 times. 
Vrečko 2 do 3-krat nežno obrnite.
, Mg including Hartman's and lactated Ringer's solutions. 
), vključno s Hartmanovo raztopino in raztopino Ringerjevega laktata.
What IVEMEND looks like and contents of the pack IVEMEND is a white to off-white powder for solution for infusion. 
Izgled zdravila IVEMEND in vsebina pakiranja Zdravilo IVEMEND je bel do sivobel prašek za raztopino za infundiranje.
Administration and infusion site reactions 
Reakcije na mestu aplikacije/infundiranja
Paediatric patients 2 to less than 12 years 
Pediatrični bolniki, stari od 2 leti do manj kot 12 let
Necrosis was also reported in some patients with concomitant vesicant chemotherapy. 
Pri nekaterih bolnikih so pri sočasni uporabi kemoterapije z vezikanti poročali tudi o nekrozi.
IVEMEND contains the active substance fosaprepitant which is converted to aprepitant in your body. 
Zdravilo IVEMEND vsebuje zdravilno učinkovino fosaprepitant, ki se v telesu pretvori v aprepitant.
245.3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant) to aprepitant, 23.9 mg of phosphoric acid and 95.3 mg of meglumine are liberated. 
Pri pretvorbi 245,3 mg dimegluminijevega fosaprepitanta (kar ustreza 150 mg fosaprepitanta) v aprepitant se sprosti 23,9 mg fosforjeve (V) kisline in 95,3 mg meglumina.
Aprepitant regimen (N =1,134) ** 
Aprepitant (N = 1.134) **
As a weak inhibitor of CYP3A4, the fosaprepitant 150 mg single dose can cause a transient increase in plasma concentrations of co-administered active substances that are metabolised through CYP3A4. 
Kot šibek zaviralec CYP3A4 lahko fosaprepitant v enkratnem 150 mg odmerku povzroči prehodno zvišanje plazemskih koncentracij sočasno uporabljenih zdravilnih učinkovin, ki se presnavljajo s CYP3A4.
Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with IVEMEND. 
Pri uporabi zdravila IVEMEND in varfarina, acenokumarola, tolbutamida, fenitoina ali drugih zdravilnih učinkovin, ki se presnavljajo s CYP2C9, svetujemo previdnost.
10 ml Type I clear glass vial with a chlorobutyl or bromobutyl rubber stopper and an aluminum seal with a grey plastic flip off cap. 
10-ml viala iz prozornega stekla tipa I z zamaškom iz klorobutilne ali bromobutilne gume, zaprta z aluminijastim obročkom in s sivo dvižno zaporko.
Blood and lymphatic system disorders febrile neutropenia, anaemia uncommon 
Bolezni krvi in limfatičnega sistema febrilna nevtropenija, anemija občasni
Musculoskeletal and connective tissue disorders muscular weakness, muscle spasms rare 
Bolezni mišično-skeletnega sistema in vezivnega tkiva mišična oslabelost, mišični krči redki
In children and adolescents (6 months to 17 years of age), the recommended dose of IVEMEND is based on the patient's age and weight. 
Priporočeni odmerek zdravila IVEMEND za otroke in mladostnike (stare od 6 mesecev do 17 let) temelji na bolnikovi starosti in telesni masi.
115 mg intravenously 
115 mg intravensko
Concomitant administration of fosaprepitant with active substances that strongly induce CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination could result in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy. 
Sočasni uporabi fosaprepitanta in zdravilnih učinkovin, ki močno inducirajo aktivnost CYP3A4 (npr. rifampicin, fenitoin, karbamazepin, fenobarbital), se je treba izogibati, saj se pri sočasni uporabi lahko zmanjšajo plazemske koncentracije aprepitanta, zaradi česar se lahko zmanjša učinkovitost zdravila.
These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3). 
Te študije niso pokazale neposrednih ali posrednih škodljivih učinkov na parjenje, plodnost, razvoj zarodka/plodu ali število in gibljivost semenčic (glejte poglavje 5.3).
Prepare an infusion bag filled with 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection (for example, by removing 105 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection from a 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection infusion bag). 
Pripravite infuzijsko vrečko s 145 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje (na primer, infuzijski vrečki z 250 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje odvzemite 105 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje).
After reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. 
Dokazano je bilo, da je po rekonstituciji in redčenju raztopina kemično in fizikalno stabilna 24 ur pri temperaturi 25 °C.
Preparation of IVEMEND 150 mg for intravenous administration: 
Priprava zdravila IVEMEND 150 mg za intravensko aplikacijo:
There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C). 
Kliničnih podatkov o farmakokinetiki aprepitanta pri bolnikih s hudo okvaro jeter (razred C po Child-Pugh-ovi klasifikaciji) ni na voljo.
Another or additional non-hormonal form of birth control should be used during treatment with IVEMEND and for up to 2 months after using IVEMEND, - cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants), - alfentanil, fentanyl (used to treat pain), - quinidine (used to treat an irregular heart beat), - irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer), - medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines), - warfarin, acenocoumarol (blood thinners; blood tests may be required), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections), - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - nefazodone (used to treat depression), - diltiazem (a medicine used to treat high blood pressure), - corticosteroids (such as dexamethasone), - anti-anxiety medicines (such as alprazolam), - tolbutamide (a medicine used to treat diabetes) 
- ciklosporin, takrolimus, sirolimus, everolimus (za zaviranje imunske odzivnosti) - alfentanil, fentanil (za zdravljenje bolečine) - kinidin (za zdravljenje nepravilnega srčnega utripa) - irinotekan, etopozid, vinorelbin, ifosfamid (zdravila za zdravljenje raka) - zdravila, ki vsebujejo derivate ergot alkaloidov, kot sta ergotamin in diergotamin (za zdravljenje migrene) - varfarin, acenokumarol (za redčenje krvi; mogoče bo treba narediti krvne teste) - rifampicin, klaritromicin, telitromicin (antibiotiki za zdravljenje okužb) - fenitoin (zdravilo za zdravljenje krčev/napadov) - karbamazepin (za zdravljenje depresije in epilepsije) - midazolam, triazolam, fenobarbital (zdravila za pomirjanje in lažje spanje) - šentjanževka (rastlinski pripravek za zdravljenje depresije) - zaviralci proteaze (za zdravljenje okužbe s HIV) - ketokonazol - razen šampona (za zdravljenje Cushingovega sindroma - če v telesu nastaja preveč kortizola) - itrakonazol, vorikonazol, posakonazol (za zdravljenje glivnih okužb) - nefazodon (za zdravljenje depresije) - diltiazem (zdravilo za zdravljenje visokega krvnega pritiska) - kortikosteroidi (kot je deksametazon) - zdravila proti strahu, tesnobi (kot je alprazolam) - tolbutamid (zdravilo za zdravljenje sladkorne bolezni)
The pharmacological effect of fosaprepitant is attributed to aprepitant. 
Farmakološki učinek fosaprepitanta je posledica delovanja aprepitanta.
Paediatric Patients Receiving 1-Day Fosaprepitant Regimen The efficacy of the 1-day fosaprepitant regimen in paediatric patients was extrapolated from that demonstrated in adults receiving the 1-day fosaprepitant regimen as described in the 1-Day Regimen of Fosaprepitant in Adults subsection. 
Pediatrični bolniki, ki so prejemali 1-dnevno shemo fosaprepitanta Učinkovitost 1-dnevne sheme fosaprepitanta pri pediatričnih bolnikih je ekstrapolirana iz učinkovitosti, ugotovljene pri odraslih, ki so prejemali 1-dnevno shemo fosaprepitanta, kot je opisano v podpoglavju "1-dnevna shema fosaprepitanta pri odraslih".
Following a single intravenous 150-mg dose of fosaprepitant administered as a 20-minute infusion to healthy adult volunteers, the mean AUC0-∞ of aprepitant was 35.0 µg•hr/ml and the mean maximal aprepitant concentration was 4.01 µg/ml. 
Po enkratnem 150 mg intravenskem odmerku fosaprepitanta v obliki 20-minutne intravenske infuzije je bila pri zdravih odraslih prostovoljcih povprečna vrednost AUC0-∞ aprepitanta 35,0 μg•h/ml, povprečna največja koncentracija aprepitanta pa 4,01 μg/ml.
Disodium edetate, polysorbate 80, lactose anhydrous, NaOH and/or HCl diluted (for pH adjustment). 
Dinatrijev edetat, polisorbat 80, brezvodna laktoza, NaOH in/ali razredčena HCl (za uravnavo pH).
The geometric mean plasma clearance of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 73 ml/min. 
Geometrično povprečje plazemskih očistkov aprepitanta po 150 mg intravenskem odmerku fosaprepitanta je bilo približno 73 ml/min.
The potential for interactions with multi-day fosaprepitant regimens are anticipated to be no greater than those for oral aprepitant regimens. 
Možnost za medsebojna delovanja med večdnevnimi shemami fosaprepitanta predvidoma ni nič večja kot med peroralnimi shemami aprepitanta.
Fosaprepitant placebo, aprepitant placebo, and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding (see section 4.2). 
Da je bila študija slepa, so uporabili fosaprepitant placebo, aprepitant placebo in deksametazon placebo (3. in 4. dan zvečer) (glejte poglavje 4.2).
In a randomized, parallel, double-blind, active-controlled study, IVEMEND 150 mg (N=1,147) was compared with a 3-day aprepitant regimen (N=1,175) in adult patients receiving a HEC regimen that included cisplatin (≥70 mg/m2). 
V randomizirani, vzporedni, dvojno slepi, z zdravilno učinkovino nadzorovani študiji so primerjali zdravilo IVEMEND 150 mg (N = 1.147) s 3-dnevnim režimom zdravljenja z aprepitantom (N = 1.175) pri odraslih bolnikih, ki so prejemali zelo emetogeno kemoterapijo, ki je vključevala cisplatin ( 70 mg/m2).